Skip to Navigation Skip to Search Skip to Content
Search All Centers

ASH 2017 Myeloma Research Update

Read Transcript Download/Print Transcript
View next

Published on January 3, 2018

How can patients navigate between treatment options with all of the recent breakthroughs in myeloma therapy? Dr. Guilherme Perini, a Brazilian hematologist, joined Patient Power at the 2017 American Society of Hematology (ASH) meeting to inform myeloma patients what testing should be done and what to discuss with their doctor in order to receive the most suitable treatment for their condition. Tune in to find out the latest from this myeloma expert.

Featuring

Transcript | ASH 2017 Myeloma Research Update

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Esther Schorr:

Hi there.  This is Esther Schorr with Patient Power.  I'm here at the American Society of Hematology in Atlanta, and with me is Dr. Perini, who is from Brazil, and he is a specialist in hematological malignancies, and we're going to talk about which ones today? 

Dr. Perini:

Myeloma. 

Esther Schorr:

Myeloma.  Okay. 

Dr. Perini:

So myeloma is a hot area right now.  There are so many drugs coming out, a lot of combinations.  Thinking about Brazil a little while, I think the most important message I can tell is that we need better certification.  So in all presentations we see that we're moving to a biological definition of high?risk patients, and these patients will benefit from the best drugs including tandem transplants.  So tandem transplant was standard for a while, then it was considered not standard but now has been shown for high-risk patients there is some hope in tandem transplants. 

Tomorrow we will see the data on the combination of daratumumab with VMP for transplant-ineligible patients.  But it's a very, very hot area now.  There are so many good news for myeloma patients. 

Esther Schorr:

So what should those myeloma patients do now with this information?  Is there something that they can discuss with their doctors? 

Dr. Perini:

Yes.  I believe the first thing on diagnosis is to get all the cytogenic analyses by FISH.  It's very important.  Less than 2 percent of patients in Brazil have this kind of information, so it's something that we have to incorporate in our practice.  And also talk to get a better tailored treatment for the patients.  We have so many new drugs now, so many new combinations, we are able now to get other factors when deciding the treatment, what's more tolerable, what is more suitable for the patient's life. 

Esther Schorr:

Very good.  And you mentioned just 2 percent of patients in Brazil have the FISH testing.  Is that something that's there's work being done to change that? 

Dr. Perini:

Yes.  First because FISH not really easy to get in Brazil and also because it's very expensive, and it's not reimbursed. 

Esther Schorr:

What is FISH? 

Dr. Perini:

Oh, FISH is the analysis.  It's a kind of cytogenic analysis.  So it's very expensive in Brazil, but it's getting better, so we're trying to convince even the payers and everything of the role of FISH in myeloma. 

Esther Schorr:

Thank you.  Thank you very much.  So that was Dr. Perini from Brazil, and this is Esther Schorr from Patient Power.  And remember, knowledge can be the best medicine of all.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

View next